Quick Answer
Edesa Biotech, Inc. reported Operating Income of -$7.91 million for fiscal year 2025.
Edesa Biotech, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.91M | -12.8% |
| 2024 | -$7.01M | +23.9% |
| 2023 | -$9.22M | +49.8% |
| 2022 | -$18.37M | +22.4% |
| 2021 | -$23.68M | -270.0% |
| 2020 | -$6.40M | -26.0% |
| 2018 | -$5.08M | +2.8% |
| 2017 | -$5.22M | -6.4% |
| 2016 | -$4.91M | -13.1% |
| 2015 | -$4.34M | -859.2% |
| 2014 | -$452.3K | +92.1% |
| 2014 | -$5.72M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.34M | -23.3% | -23.0% |
| June 30, 2025 | -$1.90M | +1.5% | -16.2% |
| March 31, 2025 | -$1.64M | +26.2% | +13.7% |
| December 31, 2024 | -$1.90M | -2.2% | +1.7% |
| June 30, 2024 | -$1.93M | +6.4% | +13.0% |
| March 31, 2024 | -$2.22M | +7.9% | -19.5% |
| December 31, 2023 | -$1.86M | +21.9% | +10.0% |
| June 30, 2023 | -$2.06M | +64.4% | +14.4% |
- Edesa Biotech, Inc. showed a decrease of -12.8% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Edesa Biotech, Inc.’s operating income has declined by 38.3% (from -$5.72 million to -$7.91 million).
- The most recent figure is from Edesa Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 12, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: